Opioid withdrawal nursing: COWS scale, MAT protocols, and NCLEX review

Opioid withdrawal will not kill a healthy adult. But telling a patient in the grip of it that they are medically stable offers little comfort: the bone pain, relentless diarrhea, anxiety, insomnia, and autonomic surge of full opioid withdrawal are genuinely distressing and, untreated, reliably drive patients to leave AMA, relapse, and — given today’s fentanyl-saturated supply — die of overdose within days of tolerance loss.

The nurse’s role in opioid withdrawal management is precise and consequential. You administer the COWS scale to time buprenorphine induction correctly, monitor vital signs and ECG intervals for methadone, titrate adjunct medications, and hold the therapeutic relationship that determines whether the patient stays long enough to start medications for opioid use disorder (MOUD). You also need to recognize the difference between opioid withdrawal and opioid overdose — two states that look nothing alike physiologically but are sometimes confused in practice.

This guide covers opioid withdrawal from pathophysiology to discharge education, with complete COWS scoring, MOUD comparison, neonatal opioid withdrawal syndrome (NOWS), and 20 NCLEX-focused high-yield tips.

For the broader substance use disorder framework — DSM-5 OUD criteria, SBIRT screening, and the full substance class comparison table — see the substance use disorders nursing reference.

Opioid use disorder context

DSM-5 OUD criteria and who is at risk

Opioid use disorder (OUD) is diagnosed when two or more of the following 11 criteria are met within a 12-month period, spanning four domains: impaired control, social impairment, risky use, and pharmacological criteria (tolerance and withdrawal). Severity is classified as mild (2–3 criteria), moderate (4–5 criteria), or severe (6 or more criteria).

The pharmacological criteria — tolerance and withdrawal — are important clinical markers but do not alone constitute a diagnosis of OUD. A patient who receives scheduled opioids for chronic pain may develop physical dependence (tolerance and withdrawal physiology) without meeting the behavioral criteria that define the disorder. This distinction matters enormously in clinical practice: physical dependence is an expected physiological adaptation, while OUD involves the loss of control and compulsive use that drive harm.

Risk factors for developing OUD include prior or current substance use disorder, personal or family history of mental health disorders, history of trauma or adverse childhood experiences, adolescent-onset opioid exposure, genetic variation in opioid receptor sensitivity, and chronic pain disorders that lead to long-term opioid prescribing.

For the full DSM-5 criteria table and disorder-level context, see the substance use disorders nursing reference.

Tolerance vs physical dependence

Tolerance is the need for increasing doses to achieve the same effect. It develops through receptor downregulation and desensitization with repeated opioid exposure. Tolerance to euphoria develops faster than tolerance to respiratory depression — a clinically dangerous asymmetry.

Physical dependence is the physiological state in which abrupt cessation or antagonist administration produces withdrawal syndrome. It is an expected consequence of regular opioid use and is not equivalent to addiction. A patient on scheduled morphine for cancer pain who develops dependence has a predictable, manageable clinical situation. The same physiology in someone with OUD carries the additional burden of behavioral drivers that make management far more complex.

Opioid withdrawal pathophysiology

The locus coeruleus and noradrenergic hyperactivity

The central mechanism of opioid withdrawal is noradrenergic hyperactivity originating in the locus coeruleus (LC), a small brainstem nucleus in the pons and the brain’s primary source of norepinephrine. Under baseline conditions, opioid receptors on LC neurons — primarily mu-opioid receptors — tonically inhibit firing. Chronic opioid exposure causes compensatory upregulation of adenylate cyclase activity and upregulation of opioid receptor numbers; the LC adapts to function normally only in the presence of opioids.

When opioids are abruptly removed — or displaced by an antagonist like naloxone — this inhibitory tone collapses. LC neurons fire in an unrestrained burst. The resulting norepinephrine surge drives nearly every symptom of opioid withdrawal: anxiety, agitation, tremor, piloerection, diaphoresis, tachycardia, hypertension, and hyperalgesia. This pathway explains why clonidine, an alpha-2 adrenergic agonist that mimics the inhibitory effect of opioids on LC neurons, provides meaningful symptomatic relief without acting on opioid receptors.

Peripheral receptor effects

Mu-opioid receptors in the gastrointestinal tract, smooth muscle, and peripheral autonomic neurons also undergo upregulation during chronic opioid use. When opioids are removed, the now-upregulated receptors and the loss of tonic opioid suppression produce a hyperactive GI state: increased motility, cramping, and diarrhea. Peripheral autonomic hyperactivity contributes to sweating, lacrimation, rhinorrhea, and piloerection (gooseflesh) — the classic physical signs.

Timeline differences by opioid type

The onset and duration of withdrawal depend heavily on the half-life of the opioid involved. This distinction is clinically critical for assessment timing and medication induction planning.

Short-acting opioids (heroin, oxycodone, hydrocodone, morphine, hydromorphone): half-life of 2–6 hours. Withdrawal symptoms begin within 6–24 hours of the last dose, peak at 36–72 hours, and largely resolve within 5–7 days. Heroin withdrawal, while intensely symptomatic, follows this shorter course.

Long-acting opioids (methadone, buprenorphine): methadone has a half-life of 24–36 hours; buprenorphine has a half-life of 24–60 hours depending on formulation. Methadone withdrawal may not begin until 36–48 hours after the last dose, peaks at 72–96 hours, and can persist for 2–3 weeks. Buprenorphine withdrawal is prolonged similarly, though typically less intense than methadone due to the partial agonist ceiling effect.

Extended-release opioid formulations (ER oxycodone, ER morphine) follow a course intermediate between the two extremes.

COWS scale: clinical administration and scoring

The Clinical Opiate Withdrawal Scale (COWS) is the validated 11-item structured assessment tool for quantifying opioid withdrawal severity. It guides clinical decision-making — particularly the timing of buprenorphine induction — and provides a shared vocabulary for team communication. COWS scores are also used to monitor response to treatment over time.

Administration instructions

The nurse observes the patient and asks targeted questions to score each item. COWS is not purely self-report: items like resting pulse rate, pupil size, and tremor require objective measurement or observation. The assessment should take 3–5 minutes when performed correctly.

When to administer COWS:

• On admission for any patient with known or suspected opioid use or dependence
• Every 4 hours during active withdrawal, or every 1–2 hours if COWS is rapidly rising or ≥13
• Before each buprenorphine induction dose (COWS must be ≥8, ideally ≥12, before giving the first buprenorphine dose)
• After dose administration, at peak onset time (60–90 minutes), to assess response

COWS item scoring

The COWS total score determines clinical urgency. A score of 5–12 indicates mild withdrawal — the patient is symptomatic but stable, and adjunct medications are typically initiated. A score of 13–24 represents moderate withdrawal with significant distress; MOUD initiation or titration is indicated. Scores of 25 and above indicate severe withdrawal requiring close monitoring, aggressive symptom management, and MOUD induction or dose escalation. Buprenorphine induction is safe once the score reaches ≥8; most protocols prefer ≥12 before initiating the first dose to reduce the risk of precipitating withdrawal in a patient with residual opioid effect.

COWS for alcohol withdrawal (CIWA-Ar) uses a different instrument entirely. For CIWA-Ar administration and alcohol withdrawal management, see the alcohol withdrawal nursing guide.

Opioid withdrawal timeline

The timing of withdrawal symptoms follows the pharmacokinetics of the specific opioid. Short-acting and long-acting opioids follow different trajectories with clinical implications for monitoring frequency and MOUD induction timing.

Clinical note on buprenorphine timing: Because buprenorphine is a partial agonist with high receptor affinity, it will displace full agonists from opioid receptors. If a full agonist is still present in sufficient concentration, this displacement precipitates abrupt, severe withdrawal. Administering buprenorphine before adequate withdrawal has developed (COWS <8) risks precipitated withdrawal. For long-acting opioids, this means the nurse may be waiting 48 hours or more after last dose before COWS reaches the induction threshold — which requires careful planning, patient education, and adequate adjunct symptom management in the interim.

Medication-assisted treatment (MOUD) protocols

Medications for opioid use disorder (MOUD) — formerly called medication-assisted treatment or MAT — are the evidence-based standard of care for OUD. MOUD reduces opioid use, overdose mortality, criminal activity, and infectious disease transmission. It is not “trading one addiction for another” — a stigmatizing misconception that nurses must actively counter. All three FDA-approved MOUD agents work through different mechanisms with different logistical requirements.

Methadone: detailed nursing considerations

Methadone is a full mu-opioid agonist with an unusually long and variable half-life (24–36 hours, sometimes longer in slow metabolizers). Its unique pharmacology creates a risk profile distinct from other opioids: because the analgesic effect wanes before the drug clears, patients may seek repeat dosing into dangerous accumulation during the first weeks of treatment.

Initial induction dosing in OTP settings is 20–30 mg on day 1, with careful observation for sedation and respiratory depression for 2–4 hours post-dose. Total day-1 dose should not exceed 30–40 mg unless the patient demonstrates clear tolerance. Daily dosing is titrated by no more than 5–10 mg every 3–5 days to a target dose that eliminates craving and withdrawal (typically 60–120 mg/day; some patients require higher).

QTc monitoring is required because methadone prolongs the cardiac QT interval via hERG potassium channel blockade. A baseline ECG is obtained before initiation. The nurse monitors for symptoms of cardiac arrhythmia (palpitations, presyncope) and repeat ECGs are ordered if dose exceeds 100 mg/day, if QTc is borderline at baseline, or if other QT-prolonging medications are added. QTc >500 ms warrants consultation and possible dose reduction; QTc >550 ms is a contraindication to continued dose escalation.

Drug interactions are clinically significant. CYP3A4 inhibitors (azole antifungals, ritonavir, clarithromycin) increase methadone plasma levels. CYP3A4 and CYP2D6 inducers (rifampin, phenytoin, carbamazepine) can precipitate withdrawal by dramatically lowering methadone levels. Benzodiazepines and CNS depressants increase respiratory depression risk.

Buprenorphine/naloxone: induction timing and administration

The critical nursing skill for buprenorphine induction is timing. The partial agonist with its high receptor affinity will bind mu-opioid receptors and displace any full agonist present. If a meaningful concentration of full agonist remains, displacing it produces precipitated withdrawal — an abrupt, intense, distressing syndrome. The COWS score is the gate.

Standard induction protocol:

1. Confirm last opioid use and substance used (helps estimate clearance timeline)
2. Administer COWS; do not give buprenorphine if COWS <8
3. Most protocols use COWS ≥12 as the optimal threshold, especially for high-potency opioids or fentanyl
4. Observe for fentanyl-specific complications: fentanyl’s high lipophilicity creates tissue reservoirs that can release unpredictably, making induction timing less reliable; some centers use a low-dose (microdosing) induction protocol (Bernese method) for patients with heavy fentanyl use
5. Administer initial dose 2–4 mg SL; observe 60–90 minutes for precipitated withdrawal or sedation
6. If no precipitated withdrawal and COWS still elevated, give additional 2–4 mg; max day-1 dose typically 8–16 mg
7. Titrate over subsequent days to suppress cravings and withdrawal (typically 16–24 mg/day maintenance)

Sublingual administration: The patient places the film or tablet under the tongue and holds it there until fully dissolved — typically 5–10 minutes. Swallowing reduces bioavailability dramatically (first-pass metabolism). No food or drink for 10 minutes prior. The nurse confirms the dose is fully absorbed before the patient leaves the administration area.

Naloxone component: The naloxone in buprenorphine/naloxone (Suboxone) has negligible sublingual absorption and does not affect the opioid action of buprenorphine when used as directed. Its purpose is abuse deterrence: if the film is dissolved and injected, the naloxone reaches systemic circulation and precipitates withdrawal in a dependent person.

Naltrexone ER (Vivitrol): pre-administration requirements

Extended-release naltrexone is an opioid antagonist administered as a 380 mg IM injection every 4 weeks. Because it competitively blocks mu-opioid receptors with no intrinsic agonist activity, it carries no dependence or abuse potential.

The critical nursing barrier is the mandatory opioid-free period. The patient must be completely opioid-free for at least 7–10 days (14 days for patients transitioning from methadone) before the first injection. A urine drug screen negative for opioids — including fentanyl and methadone — is required. Administering naltrexone to a physically dependent patient will precipitate severe opioid withdrawal within 30 minutes.

A naloxone challenge test (a small IV or SQ dose of naloxone with 20-minute observation) can be used to confirm opioid freedom before the injection if clinical uncertainty exists.

Injection administration: Naltrexone ER is a suspension that must be reconstituted with the supplied diluent immediately before use. It is administered as a deep intramuscular injection into the gluteal muscle using the supplied 1.5-inch needle. Subcutaneous injection significantly increases injection site reaction risk. Sites are rotated monthly between right and left gluteal muscles.

For drug mechanism reference across opioid pharmacology, see the nursing pharmacology reference.

Non-MAT and adjunct symptom management

While MOUD is the standard of care, adjunct medications are essential for managing the acute discomfort of withdrawal — particularly in settings where MOUD initiation is delayed, during the pre-induction period, or in patients who decline MOUD.

Clonidine (alpha-2 adrenergic agonist): Directly addresses the locus coeruleus hyperactivity mechanism by activating presynaptic alpha-2 receptors, mimicking the inhibitory opioid effect on noradrenergic neurons. Dose: 0.1–0.3 mg orally every 6 hours as needed; titrate based on symptom relief and blood pressure. Monitor blood pressure before each dose and hold if systolic BP <90 mmHg. Effective for sweating, piloerection, tachycardia, anxiety, and GI cramps. Does not relieve drug craving, insomnia, or myalgia effectively. Not FDA-approved for opioid withdrawal but widely used off-label. Transdermal clonidine patches (Catapres-TTS) provide 7 days of continuous delivery — useful for patients who may have difficulty with consistent PO dosing.

Loperamide (Imodium): Opioid receptor agonist in the GI tract that does not cross the blood-brain barrier at recommended doses. Effective for diarrhea and cramping. Standard dose 4 mg initially, then 2 mg after each loose stool, maximum 16 mg/day. Note: at supratherapeutic doses, loperamide can cause cardiac arrhythmia (QTc prolongation) — this risk has led to FDA warning and should not be minimized; doses above the recommended maximum are unsafe.

Antiemetics: Ondansetron (Zofran) 4–8 mg IV/PO every 6–8 hours for nausea and vomiting; promethazine 12.5–25 mg PO/IV/IM every 4–6 hours as an alternative (sedating — use caution in patients with respiratory concerns).

NSAIDs: Ibuprofen 400–600 mg every 6–8 hours or ketorolac for myalgias and bone aches. Avoid in patients with renal impairment, GI bleeding history, or dehydration.

Sleep and anxiety: Hydroxyzine 25–50 mg at bedtime for sleep and anxiety — non-addictive antihistamine with anxiolytic properties. Trazodone 50–150 mg at bedtime for insomnia — sedating antidepressant, off-label but commonly used. Avoid benzodiazepines unless there is a concurrent alcohol or benzodiazepine withdrawal indication; they carry significant diversion and dependence risk in patients with OUD.

IV fluids: Patients with significant vomiting and diarrhea who cannot tolerate PO intake should receive IV fluid replacement. Isotonic crystalloid (normal saline or lactated Ringer’s) with electrolyte monitoring. Assess for NPO status if vomiting prevents oral medication administration.

For broader pain management pharmacology, see the pain management nursing guide.

Neonatal opioid withdrawal syndrome (NOWS/NAS)

Neonatal opioid withdrawal syndrome (NOWS) — previously called neonatal abstinence syndrome (NAS) when caused specifically by opioids — occurs in neonates born to individuals who used opioids during pregnancy. With in-utero opioid exposure, the neonate develops physical dependence and undergoes withdrawal after birth when the placental drug supply is severed.

NOWS is expected and manageable. Importantly, opioid use in pregnancy is not an absolute contraindication to breastfeeding in patients on stable MOUD — in fact, breastfeeding reduces NOWS severity and duration. The goal is not to punish opioid use in pregnancy but to support the dyad.

Prevalence and causes

NOWS affects approximately 7 per 1,000 hospital births in the US (CDC data), though rates vary dramatically by region. Causes include heroin, prescription opioids, and MOUD (methadone and buprenorphine). NOWS occurs with MOUD exposure because the mechanism is physical dependence, not pathological drug use. Neonates born to people maintained on buprenorphine generally have NOWS of shorter duration and lower severity than those exposed to methadone.

Finnegan Neonatal Abstinence Scoring System

The Finnegan Scoring System is the most widely used validated instrument for assessing NOWS severity. It evaluates 21 signs across three systems: CNS (tremors, high-pitched cry, sleep disturbance, hyperactive Moro reflex, seizures), metabolic/vasomotor (fever, mottling, nasal stuffiness, sneezing, yawning, hiccups), and GI (poor feeding, regurgitation, loose stools, excessive sucking).

Scores are obtained every 3–4 hours during the assessment period. Most protocols require two consecutive scores ≥8 or three consecutive scores ≥7 to trigger pharmacological treatment. The nurse documenting Finnegan scores must be consistent: inter-rater reliability is a known challenge, and facilities benefit from structured training.

Manifestations of NOWS

CNS signs are the most prominent: high-pitched inconsolable crying, tremors, hypertonicity, sleep disturbance (difficulty falling and staying asleep), hyperactive Moro reflex, and — in severe cases — seizures. Autonomic signs include nasal congestion, sneezing, yawning, and temperature instability. GI signs include poor feeding, uncoordinated sucking, vomiting, and loose watery stools, which can lead to significant dehydration and failure to thrive.

Non-pharmacologic first-line care

Non-pharmacologic interventions are the first-line treatment for all neonates with NOWS and should continue even when pharmacological treatment is initiated. Evidence supports:

• Skin-to-skin contact (kangaroo care): Reduces NOWS severity scores and length of hospital stay
• Rooming-in: Keeping the neonate with the parent/caregiver rather than in the NICU reduces NOWS severity; parent presence provides constant non-pharmacologic soothing. Rooming-in models have reduced length of stay by up to 50% in published studies
• Breastfeeding: Where not contraindicated (active untreated HIV, illicit drug use beyond MOUD, certain medications), breastfeeding reduces NOWS severity. Methadone and buprenorphine transfer minimally into breast milk — this is not a contraindication
• Low-stimulation environment: Dim lighting, reduced noise, minimal handling; swaddling and gentle rocking; pacifier for non-nutritive sucking needs
• Feeding support: Frequent, on-demand feeding with high-calorie formula or breast milk if needed for poor weight gain

For broader neonatal nursing context, see the neonatal nursing reference.

Pharmacological treatment

When Finnegan scores consistently trigger the treatment threshold, pharmacological treatment is initiated:

Morphine: Most common first-line agent in US NICUs. Initiated at 0.04–0.08 mg/kg/dose every 3–4 hours; titrated upward to control symptoms. Weaned by 10–20% every 1–2 days when scores are controlled for 48 hours.

Methadone: Alternative first-line; longer half-life allows less-frequent dosing (every 12–24 hours), potentially more convenient for weaning. Initiated at 0.05–0.1 mg/kg every 6–12 hours.

Phenobarbital: Second-line, used as adjunct when opioid treatment alone is insufficient, particularly for seizure control. Clonidine is also used as an adjunct in some centers.

Treatment duration varies from days to weeks depending on severity. Discharge planning requires caregiver education on NOWS signs and safe sleep, confirmed follow-up, and social work involvement.

Nursing priorities and safety

Withdrawal vs overdose: the critical distinction

Opioid withdrawal and opioid overdose produce opposite physiological states. Confusing them leads to dangerous errors.

Opioid withdrawal is sympathomimetic hyperactivity: pupils dilated (mydriasis), vital signs elevated (tachycardia, hypertension, tachypnea, low-grade fever), diaphoretic, agitated, with GI distress. The patient is awake, often extremely uncomfortable, and has intact or heightened reflexes.

Opioid overdose is CNS and respiratory depression: pupils pinpoint (miosis), respiratory rate reduced or absent, decreased or absent LOC, hypotension, bradycardia, pale/cyanotic skin, flaccid muscle tone. The patient is unresponsive or minimally responsive.

A nurse who observes a patient with dilated pupils, elevated blood pressure, agitation, and vomiting is seeing withdrawal — not overdose. Administering naloxone to a withdrawing patient will precipitate or worsen withdrawal; it is not indicated. Conversely, a patient who is sedated with small pupils needs naloxone, not a COWS score.

Vital sign monitoring frequency

• Active withdrawal (COWS ≥5): vital signs every 1–4 hours depending on severity
• COWS ≥13: vital signs every 1–2 hours; escalate if persistent or worsening hypertension, temperature >38.5°C, or tachycardia >120 bpm unresponsive to adjuncts
• Post-MOUD induction: vital signs and sedation assessment 2 hours post-dose
• Methadone: observe 2–4 hours post-dose for respiratory depression; assess sedation and oxygen saturation

Fall risk

Opioid withdrawal patients are at significant fall risk due to severe weakness, muscle pain and ataxia, orthostatic hypotension (especially with clonidine and dehydration), and insomnia-related fatigue. Clonidine and sedating adjuncts (hydroxyzine, trazodone) compound this risk. Fall precautions apply from admission. See the fall prevention nursing guide.

IV access and fluid management

Establish IV access early. Patients with moderate-to-severe GI symptoms may progress to inability to tolerate PO medications; IV access ensures medications can continue uninterrupted. Replace estimated fluid losses from vomiting and diarrhea. Monitor electrolytes in patients with significant losses — hypokalemia and hyponatremia are possible with prolonged vomiting and diarrhea.

Documentation standards

Use person-first language throughout documentation: “patient with opioid use disorder” or “patient with OUD” — not “addict,” “drug abuser,” or “junkie.” Clinical records that use stigmatizing language contribute to bias in future care encounters. Document COWS scores with specificity: record each item score, not just the total. Document MOUD doses, timing, and observed administration. Document patient education provided and patient response.

Harm reduction approach

Harm reduction is a public health framework that accepts people where they are and prioritizes reducing drug-related harm — overdose, infectious disease, violence — rather than requiring abstinence as a precondition for care. For nurses, harm reduction is both an ethical stance and a clinical strategy.

Non-judgmental therapeutic communication

Patients with OUD frequently present having experienced judgment, shame, and inadequate care from healthcare settings. Therapeutic engagement begins with tone and language. Use motivational interviewing principles: express empathy, roll with resistance, avoid confrontation, and support self-efficacy. Never link care to willingness to “quit” — engagement itself is the first therapeutic outcome.

The SBIRT framework (Screening, Brief Intervention, and Referral to Treatment) is the evidence-based standard for integrating substance use into routine care encounters. Brief interventions use motivational interviewing techniques to enhance intrinsic motivation; they are effective even when not followed by referral acceptance.

For detailed therapeutic communication techniques, see the therapeutic communication nursing guide.

Naloxone distribution and fentanyl test strips

Every patient with OUD who is not currently maintained on MOUD — and many who are — should leave any healthcare encounter with naloxone. This includes patients who are discharged still using opioids, patients who decline MOUD, and family members of people with OUD. Naloxone education includes: when to use it, how to administer (intranasal or IM), that repeat dosing may be needed for fentanyl (which often requires 2–4 doses), and that naloxone wears off in 30–90 minutes while fentanyl lasts longer — always call 911 and stay with the person.

Fentanyl test strips (FTS) detect fentanyl in drug supplies and allow people to make more informed decisions about use. A positive FTS result does not eliminate risk but provides information. Many states have removed FTS from drug paraphernalia laws; nurses should know their state’s legal status and where patients can access strips.

Anti-stigma language reference

Patient and family education

What to expect during withdrawal

Educate patients and families that withdrawal is uncomfortable but medically manageable. Normalize the intensity of symptoms — the physical pain, insomnia, and anxiety are real and expected. Explain the timeline clearly in terms of the opioid used (short-acting vs long-acting). Reinforce that every hour of symptom tolerance builds toward medication stabilization and that leaving AMA significantly increases overdose risk: tolerance is partially lost within days, and returning to pre-withdrawal doses of fentanyl can be fatal.

MOUD adherence and expectations

Explain what MOUD will and will not feel like. Patients starting buprenorphine should understand that adequate dosing eliminates withdrawal and craving but does not produce euphoria at therapeutic doses. Encourage honesty about breakthrough cravings so dose titration can occur. For methadone patients, explain the daily clinic requirement and how take-home doses are earned over time. For naltrexone patients, explain that they must carry documentation that they are on an opioid blocker so emergency providers can plan pain management appropriately.

Relapse prevention and overdose risk

Relapse is a feature of a chronic disorder, not a moral failure. When discussing relapse risk, educate specifically about overdose prevention: tolerance to opioids drops within days of abstinence or MOUD treatment, so a return to previous doses — especially fentanyl from the illicit supply — carries extremely high overdose risk. A person who relapses after any period of abstinence should start with a much lower dose than they previously used.

Patients and household members should have naloxone and know how to use it. Never use opioids alone. If relapse occurs, call the treatment team before the next scheduled appointment.

Community resources

• SAMHSA National Helpline: 1-800-662-4357 (1-800-662-HELP) — free, confidential, 24/7 treatment referral and information service; available in English and Spanish
• SAMHSA Treatment Locator: findtreatment.gov — searchable database of treatment facilities
• Buprenorphine Treatment Practitioner Locator: samhsa.gov/medication-assisted-treatment/practitioner-program-data/treatment-practitioner-locator
• NEXT Distro / local syringe service programs: naloxone access and harm reduction supplies
• Recovery support services: peer recovery coaches, recovery community organizations, peer support apps

NCLEX high-yield tips

Summary

Opioid withdrawal is a nursing-intensive, medication-responsive clinical syndrome driven by locus coeruleus noradrenergic hyperactivity and peripheral opioid receptor upregulation. The COWS scale is the nurse’s primary assessment tool — scored objectively, administered every 1–4 hours during active withdrawal, and used to gate buprenorphine induction timing. MOUD with methadone, buprenorphine/naloxone, or naltrexone ER is the evidence-based standard of care and significantly reduces overdose mortality.

Key nursing distinctions: withdrawal produces sympathomimetic hyperactivity (dilated pupils, tachycardia, agitation), while overdose produces CNS depression (miotic pupils, respiratory depression, decreased LOC). Neonatal opioid withdrawal syndrome requires Finnegan scoring, non-pharmacologic first-line care, and pharmacological treatment when scores consistently meet threshold. A harm reduction framework — non-stigmatizing language, naloxone distribution, SBIRT — underpins all of this work and reflects a clinical reality: patients who feel respected return for care.

Lindsay Smith, AGPCNP, is a board-certified adult-gerontology primary care nurse practitioner with clinical experience in addiction medicine and harm reduction.